Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up registry of subjects treated in Gilead-sponsored trials for chronic hepatitis B
2015-001050-16Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2018
- Modality
- Small Molecules, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tenofovir disoproxil fumarate, GS-4774, vesatolimod, peginterferon alfa-2a in Chronic Hepatitis B (CHB), hepatitis B (HBV), sponsored by Gilead Sciences. Started Feb 2018; status: terminated.
02
Drugs
tenofovir disoproxil fumarateGS-4774vesatolimodpeginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)hepatitis B (HBV)
Beyond the preview
Go deeper on 2015-001050-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001050-16.